The nation of Zimbabwe has turned down a significant US health deal valued at $367m (272 million pounds) spanning five years over the United States' demand for confidential data.
The decision was revealed following a internal memorandum dated December was leaked, indicating that Head of State Emmerson Mnangagwa felt the arrangement was "skewed".
A government spokesperson later clarified that the United States was requesting biological samples for scientific study and commercial gain while was not willing to guarantee the benefits from future vaccines.
"We will now turn to the difficult and regrettable task of winding down our health assistance in Zimbabwe," remarked American envoy to Zimbabwe Pamela Tremont publicly.
Her embassy indicated the US had donated over $1.9bn in health funding to Zimbabwe over the last twenty years.
A physicians' group in Zimbabwe has appealed for further talks to reach a agreement acceptable to all parties so the country's vital HIV programme can continue.
Wider Context
Zimbabwe's decision follows a comparable case in neighbouring Kenya, where a court blocked a related deal with the US following legal challenges were filed about the safety of citizens' medical information.
After returning to the presidency last year, US President Donald Trump has reduced foreign aid and closed the key foreign aid agency.
USAID had administered aid for the US government, but Trump argued its spending was "inefficient" and his government was seeking direct bilateral agreements to boost openness and responsibility.
Based on statements, Sixteen African countries have so far signed these new agreements, representing more than $18.3bn in new funding.
Details of the Rejected Deal
This assistance for Zimbabwe was intended to funded "HIV/Aids treatment and prevention, tuberculosis, malaria, maternal and child health, and preparing for epidemics".
"We believe this cooperation might have yielded immense advantages for the people of Zimbabwe, particularly the 1.2 million men, women and children currently on HIV treatment via American-funded initiatives," Tremont said.
However, government spokesperson Nick Mangwana argued the arrangement was "unequal".
"Our nation was requested to provide its genetic material and health information over an extended period, without any equivalent guarantee of benefiting from any medical innovations – such as new medicines or tests – that could result from that provided information," his statement read.
"Put simply, our country would supply the raw materials for scientific discovery with no certainty that the final treatments would be accessible to our citizens should a new health crisis emerge."
Sovereignty and Global Health
He also said that the US's withdrawal from the global health body and its push of one-on-one deals were undermining systems previously set up via the international health agency.
Mangwana cited its Pandemic Benefit-Sharing framework created to deal with future pandemics.
"This mechanism is designed to ensure that when a country contributes its samples, the benefits – including medicines and cures – are shared equitably, not monopolised solely by those with the funds to develop them."
The government's concerns over the US deal "must not be interpreted as anti-American sentiment," he added.
"We encourage continued discussions with our American counterparts on how future collaboration could be designed in a way that respects the independence and dignity of both nations."
Health Experts Reaction
A leading public health body stated it recognised the government's concerns, but suggested that talks need to persist considering much of the nation's Aids initiatives depended on international support.
"If technical issues arise, including those relating to data governance or agreement terms, these can frequently be resolved through detailed discussion and negotiated safeguards," it said.
This impasse highlights the complex challenges between accepting much-needed international aid and safeguarding a country's data in an increasingly interconnected world.